This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

Karen Silence, PhD
Head Preclinical Product Development at argenx


Karen worked for four years at the university of Brussels developing the Nanobody platform which lead to the establishment of Ablynx, where she was the first employee. She was inventor and project leader for Caplacizumab, the first and only Nanobody approved today. After that Karen joined argenx where she was project leader for ARGX-110, ARGX-117, ARGX-119 and ARGX-120. Currently she is heading all preclinical programs at argenx taking antibodies from lead optimisation until IND filing.

Agenda Sessions

  • Co-Chairs’ Remarks

  • Engineering of Antibodies for Optimal FcRn Engagement